Form 6-K ASTRAZENECA PLC For: Jul 31
http://archive.fast-edgar.com/20140731/A42MA22CZ22WH2Z2222822DZNTJAZZN2D262
Filed on: July 31, 2014
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
- Teck Provides Update on Highland Valley Copper Operations
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share